PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE
PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCER
Exercise of Options and Total Voting Rights
GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today,...
BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP
BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP
Exercise of Options and Total Voting Rights
Additional contract for a new clinical trial
PARSORTIX SYSTEM DEMONSTRATES POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER
Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development